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Abstract
Background: Smoking is a major risk factor for lung cancer. Bilirubin, an antioxidant, is inversely associated with the risk of
diseases related to oxidative stress. This study was conducted to determine the influence of smoking and bilirubin levels on
the risk of lung cancer in the Severance cohort study.
Methods: This study included 68,676 Korean who received a health examination at Severance Health Promotion Center
from 1994 to 2004. Serum bilirubin measurements within normal range were divided into tertiles whereas smoking states
were divided as never-smokers, former smokers and current smokers. A diagnosis of lung cancer was coded as occurring
based on the report from the National Cancer Registry. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were
calculated using Cox proportional hazards model.
Results: At the end of the study period, 240 patients (men: 181, women: 59) developed lung cancer. Compared to those
with bilirubin levels $1.0 mg/dL, HRs (95% CI) for lung cancer were 2.8 (1.8–4.2) for subjects having bilirubin levels from 0.2
to 0.7 mg/dL in men. When we stratified our analysis by smoking status, bilirubin consistently showed a protective effect on
the risk of lung cancer on both never- and current smokers. Current smokers having bilirubin levels from 0.2 to 0.7 mg/dL
had a risk of lung cancer by 6.0-fold higher than never-smokers with bilirubin levels $1.0 mg/dL in men.
Conclusion: In this large prospective study, higher baseline bilirubin level in the normal range was associated with low risk
of lung cancer. Smoking and low bilirubin levels were cumulatively associated with a higher risk of lung cancer.
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Introduction
Lung cancer is the most frequent cause of cancer death among
men worldwide with an estimated age-adjusted mortality rate of
23.0 per 100,000 in the year 2008 [1]. In Korea, the mortality rate
from lung cancer was 38.7 per 100,000 among men [2]. Lung
cancer surpassed stomach cancer as the leading cause of cancer
death in 1999 [2].
Cigarette smoking is the main epidemiologically proven cause of
lung cancer [3], and approximate 80–90% of lung cancers are
attributed to cigarette smoking [4]. Smoking is a preventable risk
factor for disease burden worldwide and resulted in 5.1 million
years of potential life lost annually in the United Stated during
2000–2004 [5].
Serum bilirubin, a bile pigment, is a major breakdown product
of heme catabolism and thus highly related with hemoglobin [6,7].
Bilirubin protects lipid membranes, protein albumin and other
proteins, especially in areas of poor antioxidant defense systems
such as the myocardium and nervous system [6]. From cross-
sectional and longitudinal studies, serum bilirubin has inverse
associations with the risk of cardiovascular disease (CVD), stroke,
metabolic syndrome and cancers such as colorectal cancer and
breast cancer [8–12]. An experimental study using animal models
support a protective effect of increased bilirubin against respiratory
injury by environmental stressors [13]. Given the remarkable
antioxidant, cytoprotective, and antiinflammatory properties of
bilirubin, and the critical role of oxidative stress, we hypothesized
that higher baseline bilirubin level is associated with lower risk of
lung cancer. Only one cohort study which used UK primary care
data showed an inverse association between bilirubin and lung
cancer, but we could not find a similar Asian population-based
cohort study [14].
Smoking was associated with decreased serum bilirubin
concentrations [15]. In the relationship between serum bilirubin
and CVD, smoking was a strong risk factor that increased this
association [16]. However, there were a few population based
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studies evaluating whether smoking may affect the association
between serum bilirubin and cancers, particularly lung cancer.
This study was conducted to evaluate the relationship between
serum bilirubin levels and the risk of lung cancer and to examine
the combined effects of serum bilirubin and smoking on the risk of
lung cancer among Korean adults (age$20 years) in The
Severance cohort study.
Materials and Methods
Study subjects
The Severance cohort study included 78,615 participants (men:
40,142, women: 38,473) aged 20–93 years Korean who visited the
Health Promotion Centers at Severance Hospital located in Seoul
for routine examinations from 1994 to 2004 [17–21]. This
prospective cohort study started follow-up when people are
enrolled during baseline (1994–2004) and followed up cancer
events until 2009. People who already have cancer (n = 868), or
past history of cancer (n = 53) were excluded. We additionally
excluded subjects (N = 609) who got lung cancer before or up to 3
years after the date of the bilirubin measurement. Subjects with
missing data in the major variables (n = 5,195), hemoglobin level,
10 g/dL or .20 g/dL (n = 831), and patients with bilirubin values
below 0.18 mg/dL (3 mmol/L) for both sexes were excluded
(n = 9) [14]. Among the 71,050 participants, the potential Gilbert
syndrome group (total bilirubin .34.2 umol/L [2.0 mg/dL],
aspartate aminotransferase ,80 IU/L, alanine transaminase ,
80 IU/L, and gamma glutamyl transpeptidase [GGT],80 IU/L;
n = 665) and potential hepatobiliary disease group (total bilirubin
.34.2 umol/L or aspartate aminotransferase $80 IU/L or
alanine aminotransferase $80 IU/L or serum albumin ,3.5 g/
dL; n = 1,709) were also excluded to avoid confounding factors.
The potential Gilbert syndrome group and the potential hepato-
biliary disease group were defined according to the previous
studies [9,22]. Therefore, a total of 68,676 participants were
included in this study (Figure S1). The Institutional Review Board
of Human Research of Yonsei University approved this study.
Data collection
Demographic characteristics including age, gender, family
history and past history of clinical diseases, as well as cigarette
smoking status (never-smoker, former smoker or current smoker)
and alcohol consumption status (never-drinker and ever-drinker)
were collected via a standardized health questionnaire during a
standardized examination at Severance Hospital. Both current-
and former-smokers were asked to report the average number of
cigarettes per day they smoked at the time or had smoked earlier.
The body mass index (BMI) was calculated as weight divided by
the square of height (m2).
For clinical chemistry assays, serum was separated from
peripheral venous blood samples obtained from each participant
after 12 hours of fasting. Serum bilirubin, fasting blood glucose,
Table 1. Baseline characteristics of the study population (N= 68,676), 1994–2004a,b.
Men Women
N=35,467 N=33,209
Lung cancer Non-lung cancer Lung cancer Non-lung cancer
N=181 N=35,286 p value N=59 N=33,150 p value
Age, year 57.6 (0.8) 45.3 (0.1) ,0.0001 55.8 (1.6) 45.7 (0.1) ,0.0001
Body mass index, kg/m2 23.6 (0.2) 24.2 (0.02) 0.0162 23.1 (0.4) 23.2 (0.02) 0.6521
Serum bilirubin, mg/dl 0.8 (0.02) 0.9 (0.002) ,0.0001 0.7 (0.04) 0.7 (0.002) 0.5548
Hemoglobin, g/dl 15.3 (0.1) 15.2 (0.01) 0.3591 13.0 (0.1) 13.0 (0.01) 0.4513
White blood cell count,6103/ul 7.5 (0.1) 6.9 (0.01) ,0.0001 6.6 (0.2) 6.1 (0.01) 0.0166
Aspartate aminotransferase, IU/L 20.6 (0.6) 21.5 (0.04) 0.1273 18.5 (0.9) 18.6 (0.04) 0.9606
Alanine aminotransferase, IU/L 24.2 (1.04) 25.6 (0.1) 0.1780 16.2 (1.2) 16.8 (0.1) 0.6274
Gamma-glutamyl transpeptidase, IU/L 45.0 (3.3) 40.7 (0.2) 0.1949 15.7 (2.2) 17.9 (0.1) 0.3212
Systolic blood pressure, mmHg 126.0 (1.3) 123.7 (0.1) 0.7060 125.0 (2.3) 119.8 (0.1) 0.0240
Diastolic blood pressure, mmHg 72.2 (0.9) 73.3 (0.1) 0.2014 72.4 (1.5) 72.2 (0.1) 0.8734
Total cholesterol, mg/dl 194.1 (2.6) 194.9 (0.2) 0.7802 193.9 (4.4) 193.3 (0.2) 0.8796
HDL cholesterol, mg/dl 45.0 (0.9) 47.1 (0.1) 0.0123 50.6 (1.7) 54.6 (0.1) 0.0180
Triglyceride, mg/dl 164.9 (8.2) 163.2 (0.6) 0.8384 152.0 (9.7) 119.7 (0.4) 0.0008
Fasting blood sugar, mg/dl 98.6 (1.8) 97.4 (0.1) 0.5144 91.5 (2.6) 92.7 (0.1) 0.6333
Condition, %
Smoking status
Ex 26.5 28.5 6.8 2.9
Current 64.1 50.9 0.0002 10.2 6.3 0.0824
Alcohol drinking (yes) 74.0 83.4 0.0008 25.4 32.2 0.2667
Family history of cancer (yes) 27.1 24.2 0.3648 25.4 25.1 0.9506
aData are expressed as mean (standard error) unless otherwise indicated.
bExcept for age, all mean values were age-adjusted.
Abbreviation: HDL, high-density lipoprotein.
doi:10.1371/journal.pone.0103972.t001
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total cholesterol, and high-density lipoprotein cholesterol (HDL-C)
were measured using a Hitachi-7600 analyzer (Hitachi Ltd.,
Tokyo, Japan).
All measurements were performed by a central laboratory at
Severance Hospital, Yonsei University Health System, Seoul,
Korea. Data quality control was maintained in accordance with
the procedures of the Korean Association of Laboratory Quality
Control.
Outcome variables and follow-up
The principle outcome variable was incident lung cancer, based
on National Cancer Registry. The Korean Ministry of Health and
Welfare started a nationwide, hospital-based cancer registry in
1980 [23]. More than 180 hospitals are currently participating,
and the data covers approximately 99% of new cancer cases in
Korea. Cases were identified through a personal identification
number and other usual identification variables such as names and
addresses. The list of registered cases and a list of cancer cases
from claims made through the National Health Insurance
Corporation for each region were sent to the regional cancer
registries to find any dropped cases [23]. Cancer cases were
classified according to the International Classification of Diseases,
10th edition (ICD-10), and lung cancer was coded as C33-34
[23,24]. We followed up lung cancer events from January 1995 to
June 2009. Subjects diagnosed as cancers other than lung cancer
during follow-up or any confirmed death within data provided by
the National Statistical Office were treated as censored in this
study. We were not able to take the issue of migration into
account.
Statistical analysis
Data were expressed as mean 6 standard deviation (SD). Chi-
square test and general linear models were used for analysis of
statistical differences among the characteristics of the study
participants. To confirm combined effects of smoking status
(never-smoker, former smoker, and current smoker) and bilirubin
levels on the risk of lung cancer, serum bilirubin concentrations
were classified into tertiles (men: 0.2#T1,0.8 mg/dL, 0.8#T2,
1.0 mg/dL, 1.0#T3,2.9 mg/dL; women: 0.2#T1,0.6 mg/dL
0.6#T2,0.8 mg/dL, 0.8#T3,2.9 mg/dL). Heavy smoker is
defined by a daily cigarettes consumption of more than 20 pieces
according to the recommendations of the World Health Organi-
zation (WHO).
To examine the association between smoking, bilirubin levels
and the risk of lung cancer, Cox proportional hazard models were
examined after adjusting for age and other potential confounding
factors, including body mass index (BMI), white blood cell count,
hemoglobin, and alcohol intake. Cox proportional hazard models
were also used to calculate the risk of having lung cancer
comparing the highest and lowest tertiles of bilirubin by smoking
status. All analyses were performed using SAS statistical software,
version 9.1 (SAS Institute Inc., Cary, NC). All statistical tests were
two sided, and null hypotheses of no difference were rejected if p-
values were less than .05, or, equivalently, if the 95% CIs of
hazard ratio estimates excluded 1.
Results
Recruited into the study were 68,676 patients from 78,615, with
a median follow-up of 8.95 years. At the end of the study period,
240 patients (men: 181, women: 59) developed lung cancer
(Table 1). In the baseline characteristics of study subjects, after
adjustment for age, there were significant differences in BMI,
serum bilirubin, white blood cell count, HDL-C, smoking status,
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and alcohol consumption status between the men with and those
without lung cancer (p-value,0.05) (Table 1). However, there
were significant differences in age, white blood cell count, systolic
blood pressure, HDL-C, and triglyceride between the same groups
in women (p value ,0.05).
Table 2 shows associations of various variables with bilirubin
tertiles at baseline among men and women. After adjusting for age,
there were consistent negative relationships of bilirubin tertiles
with body mass index, white blood cell count, AST, ALT,
triglyceride and current smoking in both sexes. However, HDL-C,
hemoglobin, and alcohol drinking status were positively related to
bilirubin levels.
In multivariate Cox proportional hazard models, after adjusting
for age, BMI, white blood cell count, hemoglobin, and alcohol
intake, the lowest bilirubin tertile was significantly associated with
the risk of lung cancer compared to those in the highest tertile for
men [HR(95% CI) = 2.8 (1.8–4.2)] (Table 3). After additional
adjustment for smoking status, there was no appreciable change
found in the risk [HR(95% CI) = 2.5 (1.7–3.7)]. Current smoking
was as expected positively significantly associated with the risk of
lung cancer in both men and women (Table S1). In heavy
smokers, HR was increased up to 4.0 compared to never-smokers
among men (Table S2).
In table 4, we observed the association between serum bilirubin
level and the risk of lung cancer stratified by smoking status in
men. Regardless of smoking status, we observed similar strength of
negative associations between bilirubin and lung cancer. After we
additionally adjusted for the amount of smoking, bilirubin
consistently showed significant inverse association on the risk of
lung cancer among current smokers. When we divided current
smokers into light/medium smokers(,20cig/day) and heavy
smoker($20cig/day), we could confirm the stronger significant
association between serum bilirubin levels(per 1SD) and lung
cancer risk in heavy smokers compared to light/medium smokers
(light/medium smoker, HR (95%CI) = 0.70 (0.47–1.03); heavy
smoker, HR (95%CI) = 0.67 (0.52–0.87)) (Data not shown).
In the distribution of bilirubin levels by the amount of smoking
(per cig/day), concentrations of serum bilirubin decreased with
increasing numbers of cigarettes smoked per day in both men and
women (Figure 1).
Figure 2 illustrates the combined effects of serum billirubin and
smoking status with the risk of lung cancer in men. We found
additive model when we examining the modifying effect of
smoking on the association between serum bilirubin levels and
lung cancer risk. After adjusting for the confounders, HR(95% CI)
for the risk of lung cancer among current smokers was 1.6 (0.6–
4.3). This HR increased to 6.0 when current smokers had the
lowest tertile of bilirubin. Current smokers with the lowest tertile of
bilirubin had a 3.8-fold increase in the risk of lung cancer. It was
about 6.7-fold increase in the risk of lung cancer among
participants with the lowest tertile of bilirubin. The interactions
of the association between bilirubin and lung cancer with smoking
status were not significant. When we carried out a sub-analysis
restricted to men older than 50 years of age (N = 12,524), The HR
increased to 7.7 when current smokers had the lowest tertile of
bilirubin (Figure S2).
Discussion
After accounting for the other important health indicators
including smoking status, there was an inverse association between
serum bilirubin levels and the incidences of lung cancer in men.
Furthermore, when we combined the effect of smoking and
bilirubin, the risk of lung cancer of current smokers with the lowest
bilirubin tertile, compared to never smoker with the highest
bilirubin tertile was significantly increased. To our knowledge, this
is the first analysis of the combined effect of smoking and bilirubin
on the risk of lung cancer.
Table 4. The association between serum total bilirubin level
and the risk of lung cancer according to smoking status
among Korean mena.
HR (95% CI)
Never-smoker
Number of total/case 7278/17
1SD increase 0.6 (0.3–1.0)
Former smoker
Number of total/case 10108/48
1SD increase 0.7 (0.5–1.0)
Current smokerb
Number of total/case 18081/116
1SD increase 0.7 (0.5–0.9)
aAdjusted for age, body mass index, white blood cell count, hemoglobin, and
alcohol intake.
bAdditionally adjusted for amount of smoking(per sig/day). 706 were excluded
because of missing variable on amount of smoking.
doi:10.1371/journal.pone.0103972.t004
Figure 1. Serum bilirubin levels according to the amount of
smoking.
doi:10.1371/journal.pone.0103972.g001
Figure 2. Hazard ratio(HR) for lung cancer according to serum
bilirubin levels and smoking status in men. Cox proportional
hazard models were examined after adjusting for age, body mass index,
white blood cell count, hemoglobin, and alcohol intake. *represents
95% confidence interval of hazard ratio estimate excluded 1.
doi:10.1371/journal.pone.0103972.g002
Smoking, Bilirubin Levels and Risk of Lung Cancer
PLOS ONE | www.plosone.org 5 August 2014 | Volume 9 | Issue 8 | e103972
While bilirubin has been generally regarded as little more than a
metabolic by-product of heme degradation, epidemiologic studies
suggest a protective effect of bilirubin against cancer and cancer-
related death. One of the studies showed that each 1-mg/dL
increase in serum bilirubin is associated with a markedly decreased
prevalence of colorectal cancer (OR = 0.257; 95% CI 0.254–
0.260) [25]. However, we can find only few previous studies about
the association between bilirubin and lung cancer. A study showed
an inverse association between bilirubin levels and the incidences
of respiratory disease including lung cancer, which is consistent
with our study [14]. In that study, regression estimates for
incidence rate of lung cancer per 0.1-mg/dL increase in bilirubin
level were an 8% decrease for men and an 11% decrease for
women [14]. In our study, each 0.1 mg/dL increase in bilirubin
level was significantly associated with 8% decrease in the risk of
lung cancer incidence for men, and this study lacks statistical
power to demonstrate associations in women. Unlike most
previous studies, we provided Asian based information about the
association between bilirubin and lung cancer. Moreover, we also
evaluated whether smoking status may affect the association.
Among never-smokers, serum bilirubin was consistently inversely
associated with the risk of lung cancer. Among current smokers,
after we additionally adjusted for the amount of smoking, bilirubin
consistently showed significant protective effect on the risk of lung
cancer.
We observed increased HR of 3.8 for lung cancer in current
smoker compared with never-smoker in men (Table S1).
Compared with the HRs between smoking and lung cancer from
non-Asian based studies, this study showed small effect of smoking
on lung cancer. However, it is consistent with previous Asian
based studies. A meta-analysis study which investigated the
association between smoking and all lung cancer showed HRs
ranging from 1.22 to 5.10 in Asia including Japan and China [26].
A previous 16-year follow-up Korean cohort study suggested HR
(95%CI); 4.1 (2.1–7.9) in current smoker compared with never-
smoker [27].
In previous studies, the association between smoking and serum
bilirubin concentration has been described [28,29]. Total serum
bilirubin level was lower in male smokers and intermediate in
former-smokers compared with never-smokers in a study among
the Belgian population. However, in female smokers, lower
concentration of total serum bilirubin was found but the difference
was not significant [29].
Smoking is found to be positively associated with hemoglobin,
which regulates bilirubin concentrations [30,31]. Heme oxygenase
(HO)-1, the enzyme catalyzes the degradation of heme groups into
equimolar amounts of biliverdin, is considered an antioxidant and
cytoprotective enzyme [32]. Therefore, differences in bilirubin
level may be due to the concentration of hemoglobin. Decreased
survival of lung cancer was observed in low hemoglobin levels in
previous study. The group of patients with hemoglobin level lower
than percentile 25 had a survival rate that was below 41% [33]. In
our study, we excluded participants who had abnormal hemoglo-
bin levels and we additionally adjusted for hemoglobin in analyses,
so our results are independent of hemoglobin effect.
Decreased mitochondrial functions by bilirubin and apoptotic
action of bilirubin were consistently observed in previous studies
[6,34]. Bilirubin is regarded as a pro-oxidant showing its
cytopathic effect on TMK-1, and growth inhibition close to
50%. An arrest at G0/G1 was shown by the analysis of the cell
cycle [34]. The genetic variations of UGT1A1 can also be
associated with the effect of bilirubin on the diseases related to
oxidative stress [35].
This study has the following limitations: (i) The representative-
ness of the background population is limited because study subjects
were recruited from individuals who went to the health promotion
center to check their health status. (ii) In this study, we were not
able to take migration information into account. Because the
migration rate in Korea is less than 1%, this may not significantly
impact the result of this study. (iii) Bilirubin concentrations were
measured only once. (iv) Analysis for combined effect of smoking
and bilirubin on the risk of lung cancer was performed only among
men due to the small number of female Korean smokers.
However, our study has a few strengths. First, we analyzed a
large population with men and women. Second, the characteristics
of participants were homogenous because they were all urban
middle class. Finally, we found the combined effect of smoking and
bilirubin on the risk of lung cancer for the first time.
In conclusion, this prospective study showed higher baseline
bilirubin level whitin the normal range was associated with low risk
of lung cancer in Korean men. The highest risk of lung cancer was
observed in participants with very low levels of serum bilirubin and
current male smokers.
A bilirubin assay is available in many laboratories and is not
expensive. The results in this large cohort study support the
potential role of bilirubin to predict lung cancer. Our findings
suggest that serum bilirubin might have some protective function
against lung cancer. Furthermore, when it combined with smoking
control, it might be more effective. Further studies are needed to
confirm the association of bilirubin with various cancers including
lung cancer. Intervention trials may answer the question of the
potential for bilirubin as a therapeutic target for lung cancer.
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Figure S2 Hazard ratio(HR) for lung cancer according
to serum bilirubin levels and smoking status in men
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index, white blood cell count, hemoglobin and alcohol intake.
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